Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 2 · 25%Low 1 · 12.5%Moderate 4 · 50%High 0 · 0%

Calcineurin inhibitor vs no calcineurin inhibitor regimen

Death (any cause) · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Death · kidney transplant recipients

Low dose calcineurin inhibitors (CNI) showed no clear difference in death compared with to standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.79 [0.5, 1.27]
15 studies · 3462 participants
Moderate

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Death · kidney transplant recipients

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in death compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.09 [0.96, 1.24]
2010 participants
Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Adverse events: death · idiopathic steroid‐resistant nephrotic syndrome in children

Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.92]
1 study · 131 participants
Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Death · kidney transplant recipients

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 0.99 [0.69, 1.4]
23 studies · 5427 participants
Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Death · kidney transplant recipients

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

1 finding from 1 review

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.16 [0.71, 1.9]
11 studies · 2750 participants
Moderate

Calcineurin inhibitors ± steroids vs placebo/no treatment/supportive treatment/steroids

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes only
RR 1.69 [0.46, 6.14]
7 studies · 296 participants
Very low

Calcineurin inhibitors ± steroids vs alkylating agents ± steroids

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with alkylating agents ± steroids (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes only
RR 0.9 [0.35, 2.34]
7 studies · 394 participants
Very low